Editing the Genome to Cure Genetic Disease

Casebia combines CRISPR/Cas9 expertise and technology from CRISPR Therapeutics with access to deep disease-state knowledge and protein engineering capabilities from Bayer. Our aim: to transform the lives of patients and families affected by genetic disease.

Social Media

Casebia’s at @ASGCT today, are you? If so, come see our CSO, Andy Scharenberg chairing the “Gene Therapy Vector and Transgene Immunogenicity” education session today at 1:30pm CT.

CEO Jim Burns is at the Boston CEO Conference today @FSBoston participating in the “Therapeutic Market Focus” panel. He will be talking about gene editing and the future landscape of this dynamic industry. Catch the panel at 2pm at the @BiotechConf

Aloha from Honolulu! Abraham Scaria, Peter Nell, Barbara Wan, and Albena Kantardzhieva are engaging with their peers from around the world at the #ARVO2018 Annual Meeting to discuss and learn about each other’s sight-saving work. Enjoy the conference everyone! @ARVOinfo

What a great event last week! Casebia was proud to support an Evening of Hope to benefit the Biomedical Science Careers Program. Congratulations to all of the honorees. Casebia team with BSCP students Marcelina Nidaisy from Pine Manor College and Marcus Perry from Tufts Univ.

Amy Duross @vinetiworks leads our Technology Trends panel, discussing leading platforms across cell & gene therapy sector, feat @pfizer @casebiatx @BlueRockTx @Adaptimmune #CGDay18

See us on Twitter